Page last updated: 2024-12-08

lanosterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID246983
CHEMBL ID225111
CHEBI ID16521
SCHEMBL ID145834
MeSH IDM0012213

Synonyms (68)

Synonym
(3beta,20r)-lanosta-8,24-dien-3-ol
gtpl2746
lanosta-8,24-dien-3beta-ol
(3beta)-lanosta-8,24-dien-3-ol
(3beta,5alpha)-4,4,14-trimethylcholesta-8,24-dien-3-ol
CHEBI:16521 ,
lanosta-8,24-dien-3-ol, (3.beta.)-
lanosta-8,24-dien-3-beta-ol
ai3-23643
einecs 201-214-9
botalan base
(3-beta)-lanosta-8,24-dien-3-ol
lanostadien-3-beta-ol
lanosta-8,24-dien-3-ol, (3-beta)-
cholesta-8,24-dien-3-ol, 4,4,14-trimethyl-, (3beta,5alpha)-
lanosta-8,24-dien-3-ol, (3beta)-
nsc 60677
brn 2226449
lanster
nsc-60677
NSC60677 ,
botalan base 138
cholesta-8, 4,4,14-trimethyl-, (3.beta.,5.alpha.)-
lanosterin
lanosta-8, (3.beta.)-
lanosta-8,24-dien-3.beta.-ol
lanosta-8,24-dienol
LMST01010017
C01724
4,4',14alpha-trimethyl-5alpha-cholesta-8,24-dien-3beta-ol
79-63-0
4,4,14alpha-trimethyl-5alpha-cholesta-8,24-dien-3beta-ol
LANOSTEROL ,
lanosterol, >=93%, powder
DB03696
NCGC00164398-01
kryptosterol
C4CA2F34-1C1A-4673-AC43-E547708CB228
cryptosterol
CHEMBL225111
lanostereol
(3s,5r,10s,13r,14r,17r)-4,4,10,13,14-pentamethyl-17-[(2r)-6-methylhept-5-en-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-ol
S4755
cholesta-8,24-dien-3-ol, 4,4,14-trimethyl-, (3.beta.,5.alpha.)-
(3s,5r,10s,13r,14r,17r)-17-[(1r)-1,5-dimethylhex-4-enyl]-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-ol
unii-1j05z83k3m
1j05z83k3m ,
lanosterol [inci]
lanosterol [mi]
(3.beta.)-lanosta-8,24-dien-3-ol
SCHEMBL145834
AKOS024307002
8,24-lanostadien-3beta-ol
3beta-hydroxy-8,24-lanostadiene
DTXSID1040744
(3alpha)-4,4,14-trimethyl-cholesta-8,24-dien-3-ol
(3 beta)-lanosta-8,24-dien-3-ol
(3beta,5alpha)-4,4,14-trimethyl-cholesta-8,24-dien-3-ol
(3s,5r,10s,13r,14r,17r)-4,4,10,13,14-pentamethyl-17-((r)-6-methylhept-5-en-2-yl)-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-ol
Q414996
HY-W020033
CS-0031956
MS-27534
bdbm50459238
8,24-lanostadien-3b-ol
3b-hydroxy-8,24-lanostadiene
A929846
lanososterol

Research Excerpts

Overview

Lanosterol is a potential drug for cataracts treatment, which can reverse the aggregation of intracrystalline proteins. Lanosterol induces a physiological signal that instructs the oocyte to reinitiate meiosis.

ExcerptReferenceRelevance
"Lanosterol is a potential drug for cataracts treatment, which can reverse the aggregation of intracrystalline proteins. "( Separation and purification of lanosterol, dihydrolanosterol, and cholesterol from lanolin by high-performance counter-current chromatography dual-mode elution method.
Cao, X; Han, T; Lu, Z; Ma, X; Pan, Y; Pei, H; Wu, R; Zheng, J, 2019
)
2.24
"Lanosterol is an amphipathic molecule enriched in the lens."( Lanosterol reverses protein aggregation in cataracts.
Abagyan, R; Cai, H; Cao, G; Chen, D; Chen, XJ; Chung, C; Flagg, K; Gao, W; Granet, D; Grob, S; Hou, R; Hu, LD; Hu, X; Jefferson, J; Jin, X; Kozak, I; Li, G; Li, Y; Lin, D; Lin, Y; Liu, Y; Luo, H; Ouyang, H; Patel, SH; Perry, P; Qiu, A; Su, Z; Sun, X; Tjondro, HC; Wang, J; Wang, W; Wang, Y; Wen, C; Wu, F; Xi, YB; Yan, YB; Yang, X; Yeh, E; Zhang, K; Zhang, L; Zhao, L; Zhao, XJ; Zhu, J, 2015
)
2.58
"Lanosterol is a precursor of meiosis-activating sterols in the cholesterol biosynthetic pathway and induces a physiological signal that instructs the oocyte to reinitiate meiosis. "( Lanosterol influences cytoplasmic maturation of pig oocytes in vitro and improves preimplantation development of cloned embryos.
Jin, JX; Khoirinaya, C; Kim, GA; Lee, BC; Lee, S, 2016
)
3.32
"Lanosterol is an intermediate of cholesterol biosynthesis, which suggests a direct role in the control of cholesterol biosynthesis in nonprimates."( Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol.
Albers, M; Casari, G; Cheruvallath, Z; Deuschle, U; Haubold, B; Hoefer, M; Jackson, D; Kaiser, C; Kober, I; Koegl, M; Kranz, H; Kremoser, C; Mous, J; Otte, K; Pääbo, S; Remmel, B; Thompson, P; Voss, H, 2003
)
1.26

Effects

ExcerptReferenceRelevance
"Lanosterol, likewise, has no effects on the quadrupole splittings from position 10 of both chains."( Lanosterol and cholesterol have different effects on phospholipid acyl chain ordering.
Yeagle, PL, 1985
)
2.43

Actions

ExcerptReferenceRelevance
"Lanosterol did increase the sensitivity of human platelets, particularly to adrenaline and ADP at concentrations as low as 5 mg.L-1 when added from solutions in ethanol."( The effect of lanosterol on platelet aggregation in human platelets.
Bruckdorfer, KR; Hassall, DG; Lutton, C; Sulpice, JC, 1985
)
1.35

Treatment

ExcerptReferenceRelevance
"Treatment by lanosterol, but not cholesterol, significantly decreased preformed protein aggregates both in vitro and in cell-transfection experiments."( Lanosterol reverses protein aggregation in cataracts.
Abagyan, R; Cai, H; Cao, G; Chen, D; Chen, XJ; Chung, C; Flagg, K; Gao, W; Granet, D; Grob, S; Hou, R; Hu, LD; Hu, X; Jefferson, J; Jin, X; Kozak, I; Li, G; Li, Y; Lin, D; Lin, Y; Liu, Y; Luo, H; Ouyang, H; Patel, SH; Perry, P; Qiu, A; Su, Z; Sun, X; Tjondro, HC; Wang, J; Wang, W; Wang, Y; Wen, C; Wu, F; Xi, YB; Yan, YB; Yang, X; Yeh, E; Zhang, K; Zhang, L; Zhao, L; Zhao, XJ; Zhu, J, 2015
)
2.21

Pharmacokinetics

ExcerptReferenceRelevance
" This LC-MS/MS method was successfully applied to investigate the pharmacokinetic study of euphol in rats after intravenous (6 mg/kg) and oral (48 mg/kg) administration."( Quantitative determination of euphol in rat plasma by LC-MS/MS and its application to a pharmacokinetic study.
Gao, D; Li, Y; Ren, Y; Xie, X; Zhang, Y, 2014
)
0.4
"However,there are a fewer pharmacokinetic studies of GA,although it is closely related to the clinical application."( [Pharmacokinetics of ganoderic acids].
Liu, RM; Zhang, FF, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
" Results showed that the absolute bioavailability of euphol was approximately 46."( Quantitative determination of euphol in rat plasma by LC-MS/MS and its application to a pharmacokinetic study.
Gao, D; Li, Y; Ren, Y; Xie, X; Zhang, Y, 2014
)
0.4
" Consequently, a series of steroidal 1,4-dihydropyridine analogs 16-21 were synthesized and screened for their in vitro anti-fungal activity against three Candida species as steroids-based medications have low toxicity, less vulnerability to multi-drug resistance, and high bioavailability by being capable of penetrating the cell wall and binding to specific receptors."( Synthesis, Anti-Fungal Potency and In silico Studies of Novel Steroidal 1,4-Dihydropyridines.
Ahmedi, S; Iqbal, A; Khan, A; Manzoor, N; Siddiqui, T, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" The ovarian 4,4-dimethylsterol response was followed with regard to time and dose-response to the gonadotropins and the resumption of meiosis was evaluated using histologic sections."( Gonadotropin-induced accumulation of 4,4-dimethylsterols in mouse ovaries and its temporal relation to meiosis.
Baltsen, M, 2001
)
0.31
" glabrata, respectively), but showed little toxicity to mice liver cells at clinical dosage after 24 h of exposure, with the lowest lactate dehydrogenase and the highest ED(50) compared to four other azoles antifungal agents."( Antifungal activity of 25-azalanosterol against Candida species.
Wang, J; Wu, J, 2008
)
0.64
" The dosage and time of phenobarbital induction were critical for the enhanced production of ganoderic acids."( Enhanced biosynthetic gene expressions and production of ganoderic acids in static liquid culture of Ganoderma lucidum under phenobarbital induction.
Gu, T; Li, YB; Liang, CX; Miao, XL; Tang, YJ; Wang, JL; Xu, JW; Zhong, JJ, 2010
)
0.36
"Living zebrafish were anesthetized and exposed to ultraviolet-C (UV-C) irradiation at a dosage of 3250 mJ/cm2/d until they developed severe cataracts."( Zebrafish (Danio rerio) Is an Economical and Efficient Animal Model for Screening Potential Anti-cataract Compounds.
Chen, HC; Chen, WY; Chen, YH; Cheng, SC; Chuang, LH; Huang, CY; Jao, SW; Kuo, YK; Liu, CF; Ou-Yang, Y; Wang, NK, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
3beta-sterolA sterol in which the hydroxy group at position 3 has beta- configuration.
tetracyclic triterpenoidAny triterpenoid consisting of a tetracyclic skeleton.
14alpha-methyl steroidAny steroid carrying a 14alpha-methyl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (64)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Metabolism of steroids111135
Cholesterol biosynthesis2249
Biological oxidations150276
Phase I - Functionalization of compounds69175
Cytochrome P450 - arranged by substrate type30110
Endogenous sterols1838
Steroid Biosynthesis2142
Smith-Lemli-Opitz Syndrome (SLOS)2142
CHILD Syndrome2142
Desmosterolosis2142
Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2)2142
Lysosomal Acid Lipase Deficiency (Wolman Disease)2142
Ibandronate Action Pathway2143
Simvastatin Action Pathway2143
Pravastatin Action Pathway2143
Rosuvastatin Action Pathway2143
Alendronate Action Pathway2143
Hypercholesterolemia2142
Lovastatin Action Pathway2143
Zoledronate Action Pathway2143
Cerivastatin Action Pathway2143
Risedronate Action Pathway2143
Pamidronate Action Pathway2143
Fluvastatin Action Pathway2143
Atorvastatin Action Pathway2143
Cholesteryl Ester Storage Disease2142
Hyper-IgD Syndrome2142
Mevalonic Aciduria2142
Wolman Disease2142
Cholesterol biosynthesis and metabolism CE(14:0)2250
Cholesterol biosynthesis and metabolism CE(10:0)2250
Cholesterol Biosynthesis and Metabolism CE(12:0)2250
Cholesterol Biosynthesis and Metabolism CE(16:0)2250
Cholesterol biosynthesis and metabolism CE(18:0)2250
sterol:steryl ester interconversion (yeast)09
lanosterol biosynthesis12
Steroids metabolism ( Steroids metabolism )1627
(S)-2,3-Epoxy-squalene = Lanosterol ( Steroids metabolism )12
Cholesterol metabolism with Bloch and Kandutsch-Russell pathways039
Cholesterol Biosynthesis and Metabolism2248
Mevalonate Pathway1126
Bloch Pathway (Cholesterol Biosynthesis)929
Kandutsch-Russell Pathway (Cholesterol Biosynthesis)930
cholesterol biosynthesis I428
zymosterol biosynthesis020
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
Cholesterol biosynthesis with skeletal dysplasias014
Cholesterol synthesis disorders015
Cholesterol metabolism214
Enterocyte cholesterol metabolism111
Cholesterol biosynthesis pathway in hepatocytes1137
Ergosterol biosynthesis332
superpathway of ergosterol biosynthesis I2156
cholesterol biosynthesis II (via 24,25-dihydrolanosterol)937
sterol:steryl ester interconversion (yeast)513
zymosterol biosynthesis826
cholesterol biosynthesis I944
lanosterol biosynthesis33
cholesterol biosynthesis III (via desmosterol)939
superpathway of cholesterol biosynthesis2178
superpathway of ergosterol biosynthesis2256
sterol:steryl ester interconversion513
superpathway of sterol biosynthesis050
Nuclear receptors in lipid metabolism and toxicity03
Biochemical pathways: part I0466
Sterols biosynthesis pathway015
Cholesterol biosynthesis I118
Cholesterol biosynthesis II (via 24,25-dihydrolanosterol)117
Cholesterol biosynthesis III (via desmosterol)118

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)Potency12.58930.015823.527344.6684AID651778
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-crystallin B chainHomo sapiens (human)EC50 (µMol)1.42000.32000.87001.4200AID1386480
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lanosterol 14-alpha demethylaseCandida albicans SC5314Km7.40007.40007.40007.4000AID575758
14-alpha sterol demethylase Aspergillus fumigatusKs5.85003.10005.85008.6000AID575757; AID575759
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (79)

Processvia Protein(s)Taxonomy
regulation of programmed cell deathAlpha-crystallin B chainHomo sapiens (human)
cellular response to gamma radiationAlpha-crystallin B chainHomo sapiens (human)
response to hypoxiaAlpha-crystallin B chainHomo sapiens (human)
lens development in camera-type eyeAlpha-crystallin B chainHomo sapiens (human)
protein foldingAlpha-crystallin B chainHomo sapiens (human)
muscle contractionAlpha-crystallin B chainHomo sapiens (human)
tubulin complex assemblyAlpha-crystallin B chainHomo sapiens (human)
muscle organ developmentAlpha-crystallin B chainHomo sapiens (human)
negative regulation of gene expressionAlpha-crystallin B chainHomo sapiens (human)
negative regulation of cell growthAlpha-crystallin B chainHomo sapiens (human)
microtubule polymerization or depolymerizationAlpha-crystallin B chainHomo sapiens (human)
negative regulation of protein-containing complex assemblyAlpha-crystallin B chainHomo sapiens (human)
response to estradiolAlpha-crystallin B chainHomo sapiens (human)
negative regulation of intracellular transportAlpha-crystallin B chainHomo sapiens (human)
response to hydrogen peroxideAlpha-crystallin B chainHomo sapiens (human)
negative regulation of apoptotic processAlpha-crystallin B chainHomo sapiens (human)
negative regulation of DNA-templated transcriptionAlpha-crystallin B chainHomo sapiens (human)
protein stabilizationAlpha-crystallin B chainHomo sapiens (human)
stress-activated MAPK cascadeAlpha-crystallin B chainHomo sapiens (human)
apoptotic process involved in morphogenesisAlpha-crystallin B chainHomo sapiens (human)
negative regulation of amyloid fibril formationAlpha-crystallin B chainHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processAlpha-crystallin B chainHomo sapiens (human)
protein refoldingAlpha-crystallin B chainHomo sapiens (human)
response to heatAlpha-crystallin B chainHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid biosynthetic processLanosterol 14-alpha demethylaseHomo sapiens (human)
cholesterol biosynthetic processLanosterol 14-alpha demethylaseHomo sapiens (human)
sterol metabolic processLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of protein catabolic processLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of protein secretionLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of amyloid-beta clearanceLanosterol 14-alpha demethylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
amyloid-beta bindingAlpha-crystallin B chainHomo sapiens (human)
structural molecule activityAlpha-crystallin B chainHomo sapiens (human)
structural constituent of eye lensAlpha-crystallin B chainHomo sapiens (human)
protein bindingAlpha-crystallin B chainHomo sapiens (human)
microtubule bindingAlpha-crystallin B chainHomo sapiens (human)
identical protein bindingAlpha-crystallin B chainHomo sapiens (human)
protein homodimerization activityAlpha-crystallin B chainHomo sapiens (human)
protein-containing complex bindingAlpha-crystallin B chainHomo sapiens (human)
metal ion bindingAlpha-crystallin B chainHomo sapiens (human)
unfolded protein bindingAlpha-crystallin B chainHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
iron ion bindingLanosterol 14-alpha demethylaseHomo sapiens (human)
sterol 14-demethylase activityLanosterol 14-alpha demethylaseHomo sapiens (human)
heme bindingLanosterol 14-alpha demethylaseHomo sapiens (human)
oxidoreductase activityLanosterol 14-alpha demethylaseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenLanosterol 14-alpha demethylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
nucleusAlpha-crystallin B chainHomo sapiens (human)
nucleoplasmAlpha-crystallin B chainHomo sapiens (human)
cytoplasmAlpha-crystallin B chainHomo sapiens (human)
mitochondrionAlpha-crystallin B chainHomo sapiens (human)
lysosomeAlpha-crystallin B chainHomo sapiens (human)
cytosolAlpha-crystallin B chainHomo sapiens (human)
cell surfaceAlpha-crystallin B chainHomo sapiens (human)
Z discAlpha-crystallin B chainHomo sapiens (human)
axonAlpha-crystallin B chainHomo sapiens (human)
M bandAlpha-crystallin B chainHomo sapiens (human)
actin filament bundleAlpha-crystallin B chainHomo sapiens (human)
dendritic spineAlpha-crystallin B chainHomo sapiens (human)
perikaryonAlpha-crystallin B chainHomo sapiens (human)
extracellular exosomeAlpha-crystallin B chainHomo sapiens (human)
synaptic membraneAlpha-crystallin B chainHomo sapiens (human)
cardiac myofibrilAlpha-crystallin B chainHomo sapiens (human)
protein-containing complexAlpha-crystallin B chainHomo sapiens (human)
nucleusAlpha-crystallin B chainHomo sapiens (human)
cytoplasmAlpha-crystallin B chainHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
endoplasmic reticulum membraneLanosterol 14-alpha demethylaseHomo sapiens (human)
membraneLanosterol 14-alpha demethylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID1833889Substrate activity at Naegleria fowleri CYP51 expressed in Escherichia coli HMS-174 (DE3) assessed as Kcat/Km by spectroscopy2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Relaxed Substrate Requirements of Sterol 14α-Demethylase from
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID284044Inhibition of TPA-induced EBV-EA activation in Raji cells at 500 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Structure determination of inonotsuoxides A and B and in vivo anti-tumor promoting activity of inotodiol from the sclerotia of Inonotus obliquus.
AID1833893Substrate activity at Naegleria fowleri CYP51 expressed in Escherichia coli HMS-174 (DE3) assessed as dissociation constant by Morrison equation2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Relaxed Substrate Requirements of Sterol 14α-Demethylase from
AID671397Activity of Mycobacterium tuberculosis CYP125A1 assessed as apparent turnover number at 50 uM incubated for 1 hr at 25 degC by GC-MS method2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Substrate analog studies of the ω-regiospecificity of Mycobacterium tuberculosis cholesterol metabolizing cytochrome P450 enzymes CYP124A1, CYP125A1 and CYP142A1.
AID1386474Inhibition of alpha-crystallin B R120G mutant (unknown origin)-induced intracellular protein aggregation expressed in human HeLa cells or HLE-B3 cells at 0.4 uM incubated for 6 to 8 hrs by fluorescence microscopy relative to untreated control2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
Synthesis, Evaluation, and Structure-Activity Relationship Study of Lanosterol Derivatives To Reverse Mutant-Crystallin-Induced Protein Aggregation.
AID575759Binding affinity to 1 uM recombinant Aspergillus fumigatus AF293 sterol 14-alpha demethylase isoenzyme B from Escherichia coli membrane suspension assessed as spectral dissociation constant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID1833891Substrate activity at Naegleria fowleri CYP51 expressed in Escherichia coli HMS-174 (DE3) assessed as Kcat by spectroscopy2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Relaxed Substrate Requirements of Sterol 14α-Demethylase from
AID1386475Inhibition of alpha-crystallin B R120G mutant (unknown origin)-induced intracellular protein aggregation expressed in human HeLa cells or HLE-B3 cells at 4 uM incubated for 6 to 8 hrs by fluorescence microscopy relative to untreated control2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
Synthesis, Evaluation, and Structure-Activity Relationship Study of Lanosterol Derivatives To Reverse Mutant-Crystallin-Induced Protein Aggregation.
AID671391Binding affinity to Mycobacterium tuberculosis CYP124A1 assessed as type 1 binding mode at 0.05 to 0.2 uM by UV-visible spectrophotometry2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Substrate analog studies of the ω-regiospecificity of Mycobacterium tuberculosis cholesterol metabolizing cytochrome P450 enzymes CYP124A1, CYP125A1 and CYP142A1.
AID284043Inhibition of TPA-induced EBV-EA activation in Raji cells at 1000 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Structure determination of inonotsuoxides A and B and in vivo anti-tumor promoting activity of inotodiol from the sclerotia of Inonotus obliquus.
AID1386476Inhibition of alpha-crystallin A Y118D mutant (unknown origin)-induced intracellular protein aggregation expressed in human HeLa cells or HLE-B3 cells at 4 uM incubated for 6 to 8 hrs by fluorescence microscopy relative to untreated control2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
Synthesis, Evaluation, and Structure-Activity Relationship Study of Lanosterol Derivatives To Reverse Mutant-Crystallin-Induced Protein Aggregation.
AID1386480Inhibition of alpha-crystallin B R120G mutant (unknown origin)-induced intracellular protein aggregation expressed in human HeLa cells or HLE-B3 cells incubated for 6 to 8 hrs by fluorescence microscopy relative to untreated control2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
Synthesis, Evaluation, and Structure-Activity Relationship Study of Lanosterol Derivatives To Reverse Mutant-Crystallin-Induced Protein Aggregation.
AID1386479Inhibition of gamma-crystallin D W43R mutant (unknown origin)-induced intracellular protein aggregation expressed in human HeLa cells or HLE-B3 cells at 4 uM incubated for 6 to 8 hrs by fluorescence microscopy relative to untreated control2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
Synthesis, Evaluation, and Structure-Activity Relationship Study of Lanosterol Derivatives To Reverse Mutant-Crystallin-Induced Protein Aggregation.
AID1063365Hepatoprotective activity against D-galactosamine-induced toxicity in rat WB-F344 cells assessed as cell survival at 10 uM preincubated for 1 hr followed by D-galactosamine challenge measured after 24 hrs by MTT assay relative to normal cell2014Journal of natural products, Jan-24, Volume: 77, Issue:1
Chemical constituents from Inonotus obliquus and their biological activities.
AID671398Activity of Mycobacterium tuberculosis CYP142A1 assessed as apparent turnover number at 50 uM incubated for 1 hr at 25 degC by GC-MS method2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Substrate analog studies of the ω-regiospecificity of Mycobacterium tuberculosis cholesterol metabolizing cytochrome P450 enzymes CYP124A1, CYP125A1 and CYP142A1.
AID284047Inhibition of TPA-induced EBV-EA activation in Raji cells at 100 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Structure determination of inonotsuoxides A and B and in vivo anti-tumor promoting activity of inotodiol from the sclerotia of Inonotus obliquus.
AID1386477Inhibition of beta-crystallin B2 V187E mutant (unknown origin)-induced intracellular protein aggregation expressed in human HeLa cells or HLE-B3 cells at 4 uM incubated for 6 to 8 hrs by fluorescence microscopy relative to untreated control2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
Synthesis, Evaluation, and Structure-Activity Relationship Study of Lanosterol Derivatives To Reverse Mutant-Crystallin-Induced Protein Aggregation.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID671393Binding affinity to Mycobacterium tuberculosis CYP142A1 assessed as type 1 binding mode at 0.05 to 0.2 uM by UV-visible spectrophotometry2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Substrate analog studies of the ω-regiospecificity of Mycobacterium tuberculosis cholesterol metabolizing cytochrome P450 enzymes CYP124A1, CYP125A1 and CYP142A1.
AID1378835Antiausteritic activity against human PANC1 cells in nutrient-deprived medium assessed as decrease in cell viability measured after 24 hrs by WST-8 assay
AID322754Binding affinity to human reconstituted CYP512007Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
AID575757Binding affinity to Aspergillus fumigatus AF293 sterol 14-alpha demethylase isoenzyme B expressed in Escherichia coli assessed as spectral dissociation constant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID1527143Binding affinity to human CYP51 T314I mutant expressed in Escherichia coli assessed as decrease in demethylation incubated for 1 min2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Validation of Human Sterol 14α-Demethylase (CYP51) Druggability: Structure-Guided Design, Synthesis, and Evaluation of Stoichiometric, Functionally Irreversible Inhibitors.
AID1386478Inhibition of gamma-crystallin C G129C mutant (unknown origin)-induced intracellular protein aggregation expressed in human HeLa cells or HLE-B3 cells at 4 uM incubated for 6 to 8 hrs by fluorescence microscopy relative to untreated control2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
Synthesis, Evaluation, and Structure-Activity Relationship Study of Lanosterol Derivatives To Reverse Mutant-Crystallin-Induced Protein Aggregation.
AID284048Inhibition of TPA-induced EBV-EA activation in Raji cells at 10 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Structure determination of inonotsuoxides A and B and in vivo anti-tumor promoting activity of inotodiol from the sclerotia of Inonotus obliquus.
AID671401Activity of Mycobacterium tuberculosis CYP142A1 assessed as relative apparent turnover number at 50 uM incubated for 1 hr at 25 degC by GC-MS method relative to cholesterol2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Substrate analog studies of the ω-regiospecificity of Mycobacterium tuberculosis cholesterol metabolizing cytochrome P450 enzymes CYP124A1, CYP125A1 and CYP142A1.
AID284049Cell viability in Raji cells at 1000 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Structure determination of inonotsuoxides A and B and in vivo anti-tumor promoting activity of inotodiol from the sclerotia of Inonotus obliquus.
AID671400Activity of Mycobacterium tuberculosis CYP125A1 assessed as relative apparent turnover number at 50 uM incubated for 1 hr at 25 degC by GC-MS method relative to cholesterol2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Substrate analog studies of the ω-regiospecificity of Mycobacterium tuberculosis cholesterol metabolizing cytochrome P450 enzymes CYP124A1, CYP125A1 and CYP142A1.
AID671392Binding affinity to Mycobacterium tuberculosis CYP125A1 assessed as type 1 binding mode at 0.05 to 0.2 uM by UV-visible spectrophotometry2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Substrate analog studies of the ω-regiospecificity of Mycobacterium tuberculosis cholesterol metabolizing cytochrome P450 enzymes CYP124A1, CYP125A1 and CYP142A1.
AID1063364Hepatoprotective activity in rat WB-F344 cells assessed as inhibition of D-galactosamine-induced toxicity at 10 uM preincubated for 1 hr followed by D-galactosamine challenge measured after 24 hrs by MTT assay relative to control2014Journal of natural products, Jan-24, Volume: 77, Issue:1
Chemical constituents from Inonotus obliquus and their biological activities.
AID575758Activity of Candida albicans CYP512010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.
AID1833890Substrate activity at Naegleria fowleri CYP51 expressed in Escherichia coli HMS-174 (DE3) assessed as Km by spectroscopy2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Relaxed Substrate Requirements of Sterol 14α-Demethylase from
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (977)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990294 (30.09)18.7374
1990's116 (11.87)18.2507
2000's202 (20.68)29.6817
2010's263 (26.92)24.3611
2020's102 (10.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.58 (24.57)
Research Supply Index6.93 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index101.83 (26.88)
Search Engine Supply Index3.07 (0.95)

This Compound (41.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (0.79%)5.53%
Reviews40 (3.96%)6.00%
Case Studies4 (0.40%)4.05%
Observational0 (0.00%)0.25%
Other958 (94.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]